Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 225

Similar articles for PubMed (Select 23503473)


Tumor suppressor in lung cancer-1 (TSLC1) mediated by dual-regulated oncolytic adenovirus exerts specific antitumor actions in a mouse model.

Lei W, Liu HB, Wang SB, Zhou XM, Zheng SD, Guo KN, Ma BY, Xia YL, Tan WS, Liu XY, Wang YG.

Acta Pharmacol Sin. 2013 Apr;34(4):531-40. doi: 10.1038/aps.2012.196. Epub 2013 Mar 18.


Overexpression of tumor suppressor TSLC1 by a survivin-regulated oncolytic adenovirus significantly inhibits hepatocellular carcinoma growth.

He G, Lei W, Wang S, Xiao R, Guo K, Xia Y, Zhou X, Zhang K, Liu X, Wang Y.

J Cancer Res Clin Oncol. 2012 Apr;138(4):657-70. doi: 10.1007/s00432-011-1138-2. Epub 2012 Jan 12.


The antitumor efficacy of IL-24 mediated by E1A and E1B triple regulated oncolytic adenovirus.

Xiao LL, Wu YM, Qian J, Tan Y, Xie GL, Zhang KJ, Wang YG, Jia XY, Liu XY.

Cancer Biol Ther. 2010 Aug 1;10(3):242-50. Epub 2010 Aug 10.


HCCS1-armed, quadruple-regulated oncolytic adenovirus specific for liver cancer as a cancer targeting gene-viro-therapy strategy.

Xu HN, Huang WD, Cai Y, Ding M, Gu JF, Wei N, Sun LY, Cao X, Li HG, Zhang KJ, Liu XR, Liu XY.

Mol Cancer. 2011 Nov 1;10:133. doi: 10.1186/1476-4598-10-133.


A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.

Li B, Liu X, Fan J, Qi R, Bo L, Gu J, Qian Q, Qian C, Liu X.

J Gene Med. 2006 Oct;8(10):1232-42.


Potent antitumor effect of interleukin-24 gene in the survivin promoter and retinoblastoma double-regulated oncolytic adenovirus.

Zhang KJ, Wang YG, Cao X, Zhong SY, Wei RC, Wu YM, Yue XT, Li GC, Liu XY.

Hum Gene Ther. 2009 Aug;20(8):818-30. doi: 10.1089/hum.2008.205.


Biodistribution and safety assessment of bladder cancer specific recombinant oncolytic adenovirus in subcutaneous xenografts tumor model in nude mice.

Wang F, Wang Z, Tian H, Qi M, Zhai Z, Li S, Li R, Zhang H, Wang W, Fu S, Lu J, Rodriguez R, Guo Y, Zhou L.

Curr Gene Ther. 2012 Apr 1;12(2):67-76.


Potent and specific antitumor effect for colorectal cancer by CEA and Rb double regulated oncolytic adenovirus harboring ST13 gene.

Zhou X, Xie G, Wang S, Wang Y, Zhang K, Zheng S, Chu L, Xiao L, Yu Y, Zhang Y, Liu X.

PLoS One. 2012;7(10):e47566. doi: 10.1371/journal.pone.0047566. Epub 2012 Oct 15.


Therapeutic efficacy of an hTERT promoter-driven oncolytic adenovirus that expresses apoptin in gastric carcinoma.

Liu L, Wu W, Zhu G, Liu L, Guan G, Li X, Jin N, Chi B.

Int J Mol Med. 2012 Oct;30(4):747-54. doi: 10.3892/ijmm.2012.1077. Epub 2012 Jul 25.


A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.

Hu ZB, Wu CT, Wang H, Zhang QW, Wang L, Wang RL, Lu ZZ, Wang LS.

Cancer Gene Ther. 2008 Mar;15(3):173-82. Epub 2007 Dec 21.


Potent anti-tumor activity of telomerase-dependent and HSV-TK armed oncolytic adenovirus for non-small cell lung cancer in vitro and in vivo.

Zhang JF, Wei F, Wang HP, Li HM, Qiu W, Ren PK, Chen XF, Huang Q.

J Exp Clin Cancer Res. 2010 May 20;29:52. doi: 10.1186/1756-9966-29-52.


Combination of oncolytic adenovirus and endostatin inhibits human retinoblastoma in an in vivo mouse model.

Wang H, Wei F, Li H, Ji X, Li S, Chen X.

Int J Mol Med. 2013 Feb;31(2):377-85. doi: 10.3892/ijmm.2012.1197. Epub 2012 Nov 29.


A new oncolytic adenoviral vector carrying dual tumour suppressor genes shows potent anti-tumour effect.

Liu XR, Cai Y, Cao X, Wei RC, Li HL, Zhou XM, Zhang KJ, Wu S, Qian QJ, Cheng B, Huang K, Liu XY.

J Cell Mol Med. 2012 Jun;16(6):1298-309. doi: 10.1111/j.1582-4934.2011.01396.x.


Gene-viro-therapy targeting liver cancer by a dual-regulated oncolytic adenoviral vector harboring IL-24 and TRAIL.

Liu X, Cao X, Wei R, Cai Y, Li H, Gui J, Zhong D, Liu XY, Huang K.

Cancer Gene Ther. 2012 Jan;19(1):49-57. doi: 10.1038/cgt.2011.67. Epub 2011 Oct 7.


A novel triple-regulated oncolytic adenovirus carrying p53 gene exerts potent antitumor efficacy on common human solid cancers.

Wang X, Su C, Cao H, Li K, Chen J, Jiang L, Zhang Q, Wu X, Jia X, Liu Y, Wang W, Liu X, Wu M, Qian Q.

Mol Cancer Ther. 2008 Jun;7(6):1598-603. doi: 10.1158/1535-7163.MCT-07-2429.


Eliminating established tumor in nu/nu nude mice by a tumor necrosis factor-alpha-related apoptosis-inducing ligand-armed oncolytic adenovirus.

Dong F, Wang L, Davis JJ, Hu W, Zhang L, Guo W, Teraishi F, Ji L, Fang B.

Clin Cancer Res. 2006 Sep 1;12(17):5224-30.


Intratumor injection of oncolytic adenovirus expressing HSP70 prolonged survival in melanoma B16 bearing mice by enhanced immune response.

Ren Z, Ye X, Fang C, Lu Q, Zhao Y, Liu F, Liang M, Hu F, Chen HZ.

Cancer Biol Ther. 2008 Feb;7(2):191-95. Epub 2007 Nov 3.


A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression.

Yamasaki Y, Tazawa H, Hashimoto Y, Kojima T, Kuroda S, Yano S, Yoshida R, Uno F, Mizuguchi H, Ohtsuru A, Urata Y, Kagawa S, Fujiwara T.

Eur J Cancer. 2012 Sep;48(14):2282-91. doi: 10.1016/j.ejca.2011.12.020. Epub 2012 Jan 13.


Anti-tumor effects of an oncolytic adenovirus expressing hemagglutinin-neuraminidase of Newcastle disease virus in vitro and in vivo.

He D, Sun L, Li C, Hu N, Sheng Y, Chen Z, Li X, Chi B, Jin N.

Viruses. 2014 Feb 18;6(2):856-74. doi: 10.3390/v6020856.


Combination of bladder cancer-specific oncolytic adenovirus gene therapy with cisplatin on bladder cancer in vitro.

Wang L, Zhang Y, Zhao J, Xiao E, Lu J, Fu S, Wang Z.

Tumour Biol. 2014 Nov;35(11):10879-90. doi: 10.1007/s13277-014-2353-7. Epub 2014 Aug 2.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk